Market Size (2015)
2015
$2.66B
Vertical: HealthcareBase Year: 201711 Sections
Market Size (2015)
2015
$2.66B
Projected (2023)
2023
$5.24B
CAGR (2015–2023)
8.9%
8.9%Key Players
110+
Viscosupplementation is a method or medical procedure during which a lubricating fluid such as hyaluronic acid (HA) injection or hyaluronan injection is injected into a joint to treat symptoms of knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, ankle, and spine arthritis. The growth of the viscosupplementation market is mainly driven by the rising prevalence of knee osteoarthritis, increasing popularity of minimally invasive procedures, and the growing geriatric population. On the contrary, stringent government regulations and the rise in insurance denials for viscosupplementation are anticipated to hinder the market growth during the forecast period.
The global viscosupplementation market is expected to reach USD 5,243.19 million by 2023 from USD 3,137.79 million in 2017 and is expected to register a CAGR of 8.96% during the forecast period from 2018 to 2023. In 2017, the market was led by the Americas with 43.46% share, followed by Asia-Pacific and Europe with shares of 43.07% and 10.48%, respectively. The market in the Americas held the largest market share owing to change in the patient shift from knee replacement surgeries to minimally invasive viscosupplementation procedures for the treatment of knee osteoarthritis, the presence of major market participants and sophisticated healthcare infrastructure, and sudden increase in demand for viscosupplementation products. On the other hand, growing geriatric population, raising awareness about single-injection treatment, and increasing preference for minimally invasive surgeries (MIS) in China, India, Japan, and Australia are likely to support the profitable market growth of the Asia-Pacific region throughout the forecast period from 2018 to 2023. Europe would follow the Asia-Pacific in terms of value in the global viscosupplementation market over the forecast period attributed to the flourishing medical technology industry, the rising prevalence of obesity, growing awareness about effective treatment therapies for knee osteoarthritis, and expanding distribution network by major market participants across the UK, Germany, France, and Italy.
The global viscosupplementation market has been segmented based on hyaluronic acid type, procedure type, application, end user, and region.
On the basis of hyaluronic acid type, the stabilized hyaluronic acid segment accounted for the largest market share of 74.01% in 2017, with a market value of USD 2,322.30 million, which is projected to register a CAGR of 9.29% during the forecast period from 2018 to 2023. This is attributed to these products being highly purified, produced without using any animal-sourced materials, and zero risks of impurities. The standard hyaluronic acid segment would exhibit considerable market growth over the forecast period as these products are cost-effective and are expected to gain momentum during the forecast period from 2018 to 2023.
Based on procedure type, the three-injection procedure segment dominated the market and accounted for a revenue share of 49.51% in 2017, with market revenue of USD 1,553.54 million owing to the lower cost of these products compared to single-injection procedure products, and the shorter treatment regimen in comparison to five-injection procedure products. On the basis of application, the hip osteoarthritis segment is likely to register a comparatively higher CAGR of 9.94% during the forecast period due to the surging worldwide number of hip osteoarthritis cases as the hip is the third most susceptible site to develop osteoarthritis, after the hand and knee. By end user, in 2017, the hospitals & clinics segment held the largest position with 59.72% market share and market value of USD 1,873.84 million. Dominance is attributed to the surging number of specialty hospitals and clinics in developing countries.
The Viscosupplementation Market market is projected to grow at a CAGR of 8.9% from 2015 to 2023.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansViscosupplementation is a method or medical procedure during which a lubricating fluid such as hyaluronic acid (HA) injection or hyaluronan injection is injected into a joint to treat symptoms of knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, ankle, and spine arthritis. The rising worldwide prevalence of knee osteoarthritis, increasing popularity of minimally invasive procedures, and the growing geriatric population would facilitate market growth over the forecast period. On the flip side, stringent government regulations and a rise in insurance denials for viscosupplementation products are anticipated to restrain the market growth during the forecast period.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansResearch Process
Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, assessment, competitive landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
Primary Interviews
Region
Manufacturer
Distributor
End User
Total Number of Primary Interviews
Americas
30%
25%
45%
45
Europe
20%
22%
58%
35
Asia-Pacific
45%
30%
25%
30
Middle East & Africa
20%
30%
50%
20
Note: Above manufacturers/distributors percentage breakup includes number of respondents from all manufacturers/distributors operating in the global market, but not the number of manufacturers/distributors
Primary Research
Extensive primary research was conducted to gain a deeper insight into the market and industry performance. In this report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed over the next five to ten years.
Secondary Research
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the global viscosupplementation market. It was also used to obtain key information about major market players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources such as World Health Organization (WHO), US Department of Health and Human Services (HHS), US Food and Drug Administration (FDA), National Health Expenditure Accounts (NHEA), International Data Corporation (IDC), National Center for Biotechnology Information (NCBI), Hospital for Special Surgery (HSS), Centers for Disease Control and Prevention (CDC), and Arthritis Foundation, expert interviews, Market Research Future analysis, annual reports, SEC filings, journals, white papers, corporate presentations, company websites, some paid databases, and many others.
Market Size Estimation
Both, top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent submarkets of the overall global viscosupplementation market. The key players in the market were identified through secondary research, and their market contributions in the respective geographies were determined through primary and secondary research. This entire procedure included the study of the annual and financial reports of top market players and extensive interviews for key insights with industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All the possible parameters that affect the market have been covered in this research study, have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data has been consolidated and added with detailed inputs and analysis from Market Research Future and has been presented in this report. The following figure shows an illustrative representation of the overall market size estimation process employed for this study.
Base Year
2017
Historical Period
2015 – 2017
Forecast Period
2017 – 2023
Primary Interviews
150+
Historical data (2015–2017) and forecast period (2017–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansBargaining Power of Suppliers
The suppliers in the global viscosupplementation market are viscosupplementation product manufacturers. There are limited suppliers present in the global viscosupplementation market. Switching cost of these suppliers is medium to low, and also it varies from product to product. Moreover, suppliers are likely to enter into strategic partnerships with distributors and specialty hospitals to increase sales. Due to the high cost of viscosupplements a limited number of customers are available in the market, and very few suppliers are there to cater to the needs of the customers which leads to intense competition between the existing suppliers. However, the quality of product plays an important role in the healthcare industry as the viscosupplementation products are used to treat knee problems and expected to provide relief. However, low-quality products are likely to hamper the standard of the procedure conducted on patients, and it can cause serious damage to the patients. Hence, healthcare service providers are selective about suppliers. Due to this, the overall bargaining power of suppliers in the global viscosupplementation market is medium.
Bargaining Power of Buyers
The bargaining power of buyers is medium in the global viscosupplementation market. The market has a limited number of buyers and limited viscosupplementation product manufacturing companies to cater to the need of the buyers. However, the viscosupplementation products are highly specialized and play an important role in resolving knee related medical complications, and the buyers of the viscosupplementation market are moderately inclined towards quality products manufactured by trusted companies. As the products are manufactured for the specific medical procedure and there are very few substitutes available in the market. Also, most of the buyers are hospitals and medical institutions providers; they are price sensitive. Moreover, they can exert pressure on the manufacturers due to the low switching cost and intense rivalry in the market, which is responsible for the increased bargaining power of buyers.
Threat of New Entrants
The threat of new entrants is medium in the global viscosupplementation market. Any manufacturing company trying to enter the market is required to accept or abide by the mandatory regulatory standards. However, the budget required for research and development of a product is high as compare to other industries. Viscosupplementation products are highly specialized and manufactured to be used in specific medical procedure and majority of the customers are using products of well-established brands and they are likely to prefer established brands over new market player due to quality concerns and to maintain the quality of healthcare service, which does not comfort the new entrants to enter the market easily. However, increasing awareness about minimally invasive knee surgeries in developing countries and increasing adoption of new technology in healthcare is likely to provide a favorable environment for new entrants.
Threat of Substitutes
The threat of substitutes in the global viscosupplementation market is medium to high. Viscosupplementation products are used for performing minimally invasive knee surgeries and providing relief in knee related complications. There are limited options available in the viscosupplementation market to serve the need of the customers which eliminates the threat of substitute. However, the dosage or the number of injections used in the procedure varies from brand to brand. Also, the medium degree of switching cost decreases the threat of substitutes. The overall threat of substitutes in the global viscosupplementation market is medium to high.
Rivalry
The rivalry in the global viscosupplementation market is medium to high. The medium degree of product differentiation and a limited number of customers increases the intensity of rivalry in the market. The market is growing with a prominent growth rate and likely to provide opportunities for major players to expand their geographical boundaries which will initiate cutthroat competition between major players to capture maximum market share in the emerging markets. Major players are trying to develop less expensive products to make these products more affordable in emerging markets. Players are engaged in developing a process to lower their manufacturing and logistics cost to increase profitability and to overcome the competition. Moreover, they are also developing advanced products for differentiating their brand from their competitors.
Market estimates by geography (2023)
InsightAsia Pacific leads with $2.67B by 2023.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $79.00M | $112.33M | $162.83M | 9.5% | 3% |
| Americas | $1.19B | $1.55B | $1.96B | 6.4% | 37% |
| Asia Pacific | $1.09B | $1.69B | $2.67B | 11.9% | 51% |
| Europe | $298.14M | $362.40M | $447.24M | 5.2% | 9% |
| Total | $2.66B | $3.71B | $5.24B | 8.9% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$5.24B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Stabilized Hyaluronic Acid | $3.95B | 8.9% | 78% |
| Standard Hyaluronic Acid | $1.29B | 8.9% | 85% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Viscosupplementation Market covering market dynamics, competitive landscape, and strategic outlook.
The Viscosupplementation Market market is projected to reach $5.24B by 2023, growing at 8.9% CAGR. The Stabilized Hyaluronic Acid segment holds the largest share.
The global viscosupplementation market is growing on the preliminary backgrounds of various factors. The growth of the viscosupplementation market is mainly driven by the increasing prevalence of the patient pool suffering from knee osteoarthritis, the rising popularity of minimally invasive procedures, and increasing geriatric population.
Knee osteoarthritis is a common disease and is one of the leading causes of disability among the geriatric population. With the increase in the age of the general population, there is a growing prevalence of knee osteoarthritis. People with obesity, diabetes, hypertension, renal failure, cardiovascular diseases, gastrointestinal bleeding, depression, and trauma in joints due to repetitive movements are subject to high risk due to knee osteoarthritis.
According to the report published by the Arthritis Foundation, osteoarthritis is the most common type of arthritis and affects more than 30 million Americans. Approximately 13% women and 10% men aged 60 years and above have symptomatic knee osteoarthritis.
The prevalence of osteoarthritis is less in men compared to women. Smoking, injuries, poor nutrition, and changing lifestyles are also some of the other factors that are increasing the causes of osteoarthritis and osteoporosis among the younger population. Therefore, there is a proportionate need for faster disease diagnosis to treat these conditions. The use of viscosupplementation is expected to grow significantly during the forecast period.
The rapid expansion of healthcare facilities could be seen in many developing economies such as China, India, South Africa, and Brazil, mainly due to the rise in the number of chronic diseases such as osteoarthritis among the elderly population. Governments in these countries are rapidly expanding and investing in healthcare facilities, which has affected the market positively.
Investments from private investors would also have a positive impact on the growth of the market, as it would help in product extension for vendors. The distribution network for viscosupplementation is likely to be enhanced in these emerging nations due to high untapped market potential, which vendors are likely to utilize during the forecast period. The increasing migration of R&D facilities from Western countries to developing APAC nations being a stable economy and less capital and labor costs in the region would lead to high demand for these products in APAC
Viscosupplementation devices are subjected to government regulations such as the FDA in the US, CE marking in Europe, and other regulations in different regions and countries worldwide. The commercialization of viscosupplementation products with different technologies is a challenging process, and the products come under class III (tests are subject to the greatest level of scrutiny) under the FDA regulation and are considered high-risk devices in Europe. They require premarket approval from notified bodies, including private organizations recognized by the European Free Trade Association. Therefore, they cannot be marketed without completing clinical trials, which are time-consuming, expensive, and uncertain. The laws and regulations of the approval process for viscosupplementation devices vary across all countries, which is a major challenge faced by multinational companies. Also, any change in regulatory policies by governing bodies during the product development process could delay the entry of new products in the market. Several developed countries such as the US, the UK, Germany, France, Japan, Singapore, and South Korea have strict regulations regarding the approval and marketing of diagnostic products. In high-income countries or developed countries, the cost of clinical trials and product launch is expensive, and this increases the spending for vendors. Many small vendors or startup medical device companies seek government or private funding, but most of the organizations provide limited funds or grants to vendors. Thus, stringent government regulations in different countries related to the market would hamper the development of viscosupplements.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 110 companies operating in the Viscosupplementation Market market, including revenue, employee count, and market positioning where available.
Showing 110 of 110 companies
Regen Lab SA
Company Headquarters: Zurich, Switzerland Founded: 2003 Workforce: 51-200 Company Working: Regen Lab SA is into manufacturing and marketing of high-quality medical devices, intended for cell therapies and the preparation of autologous platelet-rich plasma (PRP). It offers technological platforms for medical and academical purposes and offers products related to therapeutic areas such as orthopedics, skin care, chronic wounds, sports medicine, bone reconstruction, hair regeneration, plastic surgery, and veterinary. The company has regional offices in New York (US), Montreal (Canada), Venice (Italy), Munich (Germany), Paris (France), Dubai (UAE), and Beijing (China) to cater to the needs of established markets.
Bioventus LLC
Company Headquarters: Durham, North Carolina, US Founded: 2012 Workforce: 700+ Company Working: Bioventus is a major player in the orthobiologics sector. It offers bone stimulation devices, osteoarthritis joint fluid therapies, allogenic morphogenetic proteins, orthobiologics, bone grafts, and allografts to customers all over the world. It operates in business segments including ultrasound bone healing, joint therapies, and bioventus surgical.
Fidia Farmaceutici s.p.a.
Company Headquarters: Abano Terme, Veneto, Italy Founded: 1946 Workforce: 1001-5000 Company Working: Fidia Farmaceutici s.p.a. manufactures, markets, develops, and sells medical devices, medical products, and dietary supplements based on hyaluronic acid and its derivatives. The company has its distribution networks in the EMEA, Asia, and the US. It sells its products in more than 70 countries and has three international subsidiaries. Its products have been marketed for over 70 years and have prominent brand recognition. It provides products and services to private laboratories, clinics, physicians’ offices, and hospitals and critical care centers, through direct sales and a wide network of distributors across the world.
Anika Therapeutics Inc.
Company Headquarters: Massachusetts, US Founded: 1992 Workforce: ~133 Company Working: Anika Therapeutics is an orthopedic and regenerative medicines company. Its offers products based on hyaluronic acid, biocompatible polymer, and natural chemical. In the US, the company owns 19 patents and internationally 187 patents. In 2018, the company’s top five customers account 86% of the revenue, e.g., Mitek, a part of Johnson & Johnson medical device company and the global leader in orthopedic sports medicine accounted 73% of the company sales revenue. The company primarily depends on a small number of large customers, particularly Mitek, for the majority of its sales revenues. The company markets and distribute its products in the US, Italy, and European countries, among others.
Allergan
Company Headquarters: Dublin, Ireland Founded: 2013 Workforce: ~16,900 Company Working: Allergan is a leading global pharmaceutical company. The company is engaged in the manufacturing and commercialization of hyaluronic acid for medical products, devices, biologics, and surgical products for patients across the world. It operates through three business segments, namely US Specialized Therapeutics, US General Medicine, and International. The company sells its products primarily to the retailers and distributors including food store chains and national retail drug. The prime customers are hospitals, clinics, and government agencies as well as managed healthcare providers, such as health maintenance organizations and other institutions. The company has operations in 100 countries. The US and Canada account for around 10% of the company’s revenue. The three prominent customers of the company are McKesson Corporation, which accounted for around 25% of the sales revenue; Cardinal Health, Inc with 23%; and AmerisourceBergen Corporation with 22% in 2018. In addition, the company has development and manufacturing centers of raw materials, intermediate ingredients, and active pharmaceutical ingredients. Its manufacturing plants are located in Ireland, the US, Brazil, Belgium, France, and Costa Rica.
Zimmer Biomet
Company Headquarters: Warsaw, Indiana, (US) Founded: 1927 Workforce: 19,000+ Company Working: Zimmer develops, produces, and markets musculoskeletal healthcare products. It is a leading brand in providing customized joint and bone healthcare solutions. It offers products related to orthopedics, healthcare, medical instruments, medical technology, surgical instruments, medical supplies, medical devices, innovation, and signature solutions. The company is present in all major markets and holds significant market share in the global tissue engineering market.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Viscosupplementation Market